País: Israel
Idioma: anglès
Font: Ministry of Health
TAMSULOSIN HYDROCHLORIDE
CTS LTD
G04CA02
TABLETS PROLONGED RELEASE, FILM COATED
TAMSULOSIN HYDROCHLORIDE 0.4 MG
PER OS
Required
ASTELLAS PHARMA EUROPE B.V, THE NETHERLANDS
TAMSULOSIN
TAMSULOSIN
Lower urinary tract symptoms ( LUTS) associated with benign prostatic hyperplasia (BPH).
2022-01-31
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) – 1986 The medicine is dispensed with a doctor’s prescription only OMNIC OCAS 0.4 Prolonged-release film-coated tablets The active ingredient and its quantity per dosage unit: Tamsulosin Hydrochloride 0.4 mg/tablet For a list of the inactive and allergenic ingredients in the preparation - see section 6. READ THE LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE MEDICINE. This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them even if it seems to you that their medical condition is similar. The medicine is not intended for children or adolescents below the age of 18 . 1. WHAT IS THE MEDICINE INTENDED FOR? The medicine is intended for the treatment of functional disorders of the lower urinary tract associated with benign prostatic hyperplasia (BPH). THERAPEUTIC GROUP: Selective alpha 1A/1D -adrenoreceptor antagonist. The mode of action of the active ingredient of the preparation is to reduce tension of the smooth muscles in the prostate and urethra, enabling urine to pass more readily through the urethra and thereby facilitating urination. In addition, it diminishes sensations of urge. 2. BEFORE USING THE MEDICINE: X XDO NOT USE THE MEDICINE IF: • you are sensitive (allergic) to the active ingredient tamsulosin or to any of the other ingredients contained in the medicine. Hypersensitivity may present as sudden local swelling of the soft tissues of the body (e.g., the throat or tongue), difficulty in breathing and/or itching and rash (angioedema). • you suffer from severe liver problems. • you suffer from fainting due to decreased blood pressure when changing posture, for example when transitioning to a standing or sitting position. ! SPECIAL WARNINGS REGARDING USE OF THE MEDICINE • Consult with the doctor before taking the medicine. • In rare cases, as wit Llegiu el document complet
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Omnic Ocas 0.4 ® , prolonged release tablets, film-coated 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged release film-coated tablet contains 0.4 mg tamsulosin hydrochloride. For excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated, prolonged release tablet. (Oral Controlled Absorption System, OCAS). Approximately 9 mm in diameter, round, bi-convex, yellow, film-coated and debossed with the code ‘04’. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oral Use. One tablet daily. Omnic Ocas 0,4 can be taken independently of food. The tablet must be swallowed whole and not be crunched or chewed as this interferes with the prolonged release of the active substance. No dose adjustment is warranted in renal impairment. No dose adjustment is warranted in patients with mild to moderate hepatic insufficiency (see also 4.3 Contraindications). Paediatric population: There is no relevant indication for use of Omnic Ocas 0.4 in children. The safety and efficacy of tamsulosin in children <18 years have not been established. Currently available data are described in section 5.1. 4.3 CONTRA-INDICATIONS Hypersensitivity to tamsulosin hydrochloride, including drug induced angioedema or to any of the excipients listed in section 6.1. A history of orthostatic hypotension. Severe hepatic insufficiency. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE As with other α 1 -adrenoceptor antagonists, a reduction in blood pressure can occur in individual cases during treatment with Omnic Ocas 0,4, as a result of which, rarely, syncope can occur. At the first signs of orthostatic hypotension (dizziness, weakness), the patient should sit or lie down until the symptoms have disappeared. Before therapy with Omnic Ocas 0,4 is initiated, the patient should be examined in order to exclude the presence of other conditions, which Llegiu el document complet